mong
infl
ammatori
process
trigger
copd
exacerb
respiratori
tract
viral
infect
prime
suspect
although
fi
rst
local
upperrespiratori
tract
urt
infect
could
trigger
cascad
infl
ammatori
event
lead
clinic
signifi
cant
exacerb
current
guidelin
recommend
administr
antibiot
base
mainli
clinic
criteria
lead
inevit
overus
antibiot
estim
occur
approxim
acut
exacerb
copd
aecopd
particip
viral
infect
aecopd
confi
rmed
mani
studi
recent
report
use
polymeras
chain
reaction
pcr
base
method
led
posit
detect
viral
nucleic
acid
aecopd
case
howev
role
recent
identifi
ed
virus
coronaviru
human
bocaviru
well
new
human
rhinovirus
c
report
frequent
one
circul
commun
yet
fulli
establish
biomark
procalcitonin
pct
elev
propos
surrog
marker
bacteri
diseas
within
normal
valu
often
consid
clinic
practic
signatur
viral
infect
although
pct
studi
background
respiratori
virus
frequent
recov
upperrespiratori
tract
acut
exacerb
copd
aecopd
role
contribut
pathogen
remain
unclear
use
procalcitonin
creactiv
protein
indic
presenc
absenc
viral
infect
set
also
need
evalu
method
studi
prospect
cohort
patient
copd
admit
ed
aecopd
revers
transcriptasepolymeras
chain
reaction
rtpcr
respiratori
virus
perform
nasopharyng
swab
collect
admiss
recoveri
stabl
condit
conclus
preval
upperrespiratori
viral
infect
detect
nasopharyng
swab
rtpcr
high
aecopd
low
clinic
recoveri
suggest
aecopd
frequent
trigger
viral
infect
initi
upperrespiratori
tract
studi
serum
procalcitonin
creactiv
protein
discrimin
virusassoci
exacerb
other
trial
registr
clinicaltrialsgov
identifi
er
abbrevi
aecopd
acut
exacerb
copd
crp
creactiv
protein
odd
ratio
pcr
polymeras
chain
reaction
pct
procalcitonin
pef
peak
expiratori
fl
ow
rsv
respiratori
syncyti
viru
rtpcr
revers
transcriptasepolymeras
chain
reaction
urt
upperrespiratori
tract
per
high
power
fi
eld
squamou
epitheli
cell
per
low
power
fi
eld
avoid
contamin
oral
fl
ora
present
studi
report
qualit
result
studi
protocol
approv
institut
research
ethic
committe
written
inform
consent
obtain
particip
hospit
patient
monitor
daili
use
diari
card
record
respiratori
symptom
dyspnea
sever
accord
medic
research
council
dyspnea
scale
pef
oxygen
satur
puls
oximetri
measur
daili
supervis
studi
nurs
healthrel
qualiti
life
assess
use
st
georg
respiratori
questionnair
maugeri
foundat
respiratori
failur
questionnair
treatment
antibiot
oral
glucocorticosteroid
left
discret
attend
physician
blind
result
viral
screen
predetermin
followup
visit
schedul
month
mean
sd
day
initi
exacerb
patient
underw
second
assess
virolog
test
pef
measur
complet
healthrel
qualityoflif
questionnair
bacteriolog
analys
repeat
mainli
larg
major
patient
unabl
produc
sputum
nasopharyng
swab
pool
nasopharyng
pharyng
swab
perform
accord
standard
oper
procedur
studi
nurs
obtain
admiss
within
h
followup
visit
qualit
revers
transcriptasepcr
rtpcr
assay
perform
l
specimen
follow
differ
respiratori
virus
infl
uenza
b
respiratori
syncyti
viru
rsv
parainfl
uenza
human
picornavirus
human
rhinoviru
enteroviru
human
metapneumoviru
coronavirus
bocaviru
assay
conduct
previous
describ
parainfl
uenza
detect
use
recent
describ
assay
picornaviru
pcr
assay
design
detect
human
enterovirus
rhinovirus
includ
human
rhinoviru
c
discrimin
rhinovirus
enterovirus
rhinopharyng
symptom
refer
presenc
nasal
congest
increas
rhinorrhea
sore
throat
copd
sever
quantifi
ed
accord
global
initi
obstruct
pulmonari
diseas
guidelin
base
recent
spirometr
test
year
use
diari
card
time
recoveri
calcul
interv
enrol
studi
time
patient
consid
return
baselin
clinic
condit
comparison
group
perform
use
unpair
test
mannwhitney
test
x
test
fisher
exact
test
appropri
logist
regress
perform
analyz
relationship
independ
variabl
presenc
viral
nucleic
acid
adjust
signifi
cant
potenti
confound
cox
regress
model
perform
predict
mortal
accord
presenc
virus
result
present
odd
ratio
or
hazard
ratio
ci
statist
analys
perform
use
spss
version
window
statist
softwar
spss
inc
chicago
il
june
decemb
patient
screen
admiss
ed
potenti
predict
respons
antibiot
therapi
respiratori
tract
infect
never
systemat
correl
virolog
investig
assess
abil
discrimin
bacteri
viral
etiolog
exacerb
aim
describ
role
virus
includ
recent
identifi
ed
strain
knowledg
never
studi
set
pathogen
copd
document
presenc
acut
phase
exacerb
disappear
recoveri
clinic
stabl
phase
patient
also
aim
explor
potenti
biolog
marker
creactiv
protein
crp
pct
distinguish
viral
nonvir
infect
aecopd
june
decemb
prospect
recruit
adult
patient
admit
emerg
depart
hospit
sever
aecopd
accord
global
initi
chronic
obstruct
pulmonari
diseas
defi
nition
patient
identifi
ed
review
admiss
code
dyspnea
histori
copd
exclus
criteria
studi
presenc
chronic
lung
diseas
copd
asthma
bronchiectasi
pulmonari
fi
brosi
pneumoconiosi
acut
pulmonari
embol
acut
pneumonia
base
chest
radiograph
acut
pulmonari
edema
orotrach
intub
requir
peak
expiratori
fl
ow
pef
valu
number
exacerb
previou
year
report
famili
physician
person
contact
use
glucocorticosteroid
antibiot
vaccin
histori
recent
spirometr
valu
year
presenc
comorbid
preced
hospit
record
studi
inclus
serum
pct
kryptor
pct
brahm
diagnostica
gmbh
henningsdorf
germani
crp
blood
cell
count
blood
ga
analysi
sputum
bacteri
analysi
blood
chemistri
obtain
admiss
avail
result
sputum
bacteri
cultur
semiquantit
assay
consid
signifi
cant
presenc
document
bacteri
infect
colon
coinfect
viru
note
patient
alreadi
receiv
antibiot
virusposit
virusneg
group
compar
regard
baselin
characterist
except
patient
viral
infect
report
less
frequent
copd
exacerb
previou
year
shorter
durat
symptom
admiss
tabl
symptom
rhinopharyng
report
n
case
neg
viral
assay
n
case
viral
infect
document
probabl
identifi
viru
aecopd
three
time
higher
presenc
symptom
rhinopharyng
tabl
found
statist
signifi
cant
differ
patient
without
virusassoci
aecopd
term
time
clinic
recoveri
length
hospit
stay
mortal
tabl
patient
respiratori
viral
infect
put
antibiot
often
longer
period
tabl
followup
period
patient
die
n
virusposit
group
n
virusneg
group
cox
regress
model
trend
toward
higher
mortal
found
patient
viral
infect
hazard
ratio
ci
associ
disappear
fev
age
ad
model
crp
pct
valu
obtain
patient
respect
fi
case
without
pct
valu
two
virusposit
group
three
virusneg
group
patient
median
serum
crp
level
aecopd
mgl
rang
mgl
enrol
studi
fig
seventyon
patient
complet
followup
repeat
viral
sampl
avail
baselin
clinic
condit
outcom
accord
presenc
absenc
virus
shown
tabl
rtpcr
pcr
viral
assay
perform
initi
nasopharyng
specimen
show
overal
posit
rate
n
followup
visit
month
index
aecopd
virus
identifi
ed
eight
patient
p
fi
eight
patient
viru
identifi
ed
index
exacerb
thu
suggest
new
viral
infect
acquir
followup
period
human
picornavirus
frequent
encount
virus
follow
metapneumoviru
coronavirus
fig
result
suggest
dual
viral
infect
found
three
patient
season
variat
distribut
implic
virus
season
variabl
sampl
depict
figur
respect
bulk
sampl
enrol
perform
autumn
therefor
followup
occur
frequent
winter
month
bacteriolog
analys
sputum
sampl
avail
case
unabl
produc
sputum
met
microscop
criteria
bacteriolog
valid
case
posit
cultur
follow
bacteria
pseudomona
aeruginosa
n
haemophilu
infl
uenza
n
escherichia
coli
n
moraxella
catarrhali
n
streptococcu
pneumonia
n
staphylococcu
aureu
n
klebsiella
pneumonia
n
seven
case
use
larg
panel
molecular
assay
identifi
ed
respiratori
virus
urt
patient
aecopd
sampl
repeat
clinic
recoveri
patient
viru
detect
rate
drop
high
rate
viral
infect
detect
nasopharyng
swab
aecopd
upper
rang
report
publish
literatur
fi
nding
viral
infect
rate
markedli
lower
patient
recov
clinic
support
hypothesi
pathogen
role
virus
initi
identifi
ed
aecopd
one
particular
interest
studi
resid
fact
median
pct
gl
rang
gl
presenc
document
bacteri
infect
irrespect
detect
virus
urt
crp
pct
median
valu
mgl
rang
mgl
gl
rang
gl
respect
presenc
virus
aecopd
median
valu
serum
crp
pct
mgl
rang
mgl
gl
rang
gl
respect
valu
differ
signifi
cantli
compar
patient
without
bacteri
infect
p
p
respect
patient
without
viral
infect
p
p
respect
fig
includ
copd
investig
use
larg
panel
molecular
assay
use
new
pcr
identifi
ed
new
virus
never
studi
set
coronaviru
coronaviru
taken
togeth
virus
correspond
import
proport
detect
case
clinic
relev
viral
bacteri
infect
identifi
ed
urt
sampl
vs
sputum
sampl
inde
debat
howev
clinic
set
repres
sputum
aecopd
often
diffi
cult
obtain
furthermor
bacteri
colon
may
contamin
thu
inhibit
viral
cultur
sputum
sampl
well
rtpcr
rtpcr
assay
use
sputum
face
technic
limit
lack
standard
unknown
reproduc
addit
potenti
pathogen
virus
rare
found
lower
airway
bocaviru
rhinoviru
would
overlook
search
sputum
mani
limit
overcom
nasopharyng
sampl
demand
limit
patient
collabor
final
nasopharyng
area
consid
appropri
site
detect
viral
replic
lower
respiratori
tract
replic
absenc
urt
infect
except
determin
whether
upperrespiratori
viral
infect
caus
agent
aecopd
major
import
inde
detect
viral
nucleic
acid
upperrespiratori
secret
proof
per
se
causal
relationship
substanti
evid
support
role
respiratori
virus
promot
infl
ammatori
process
lead
exacerb
also
establish
virus
rsv
may
directli
infect
lower
airway
patient
copd
causal
relationship
viral
infect
initi
upperrespiratori
tract
exacerb
demonstr
small
experiment
studi
four
patient
stabl
copd
infect
rhinovirus
thu
virus
detect
nasopharyng
swab
patient
aecopd
play
role
develop
respiratori
symptom
either
alon
cofactor
pathogen
nonbiolog
agent
air
pollut
tobacco
smoke
importantli
concord
nasopharyng
swab
lowerrespiratori
tract
sampl
found
high
particularli
respiratori
virus
addit
virus
detect
urt
suspect
causal
agent
communityacquir
pneumonia
viral
infect
clear
case
followup
observ
prolong
viral
shed
report
studi
prolong
shed
mainli
describ
rsv
small
number
case
observ
studi
viral
sampl
unlik
previou
studi
collect
acut
exacerb
phase
also
systemat
collect
sever
month
initi
exacerb
patient
control
noteworthi
neither
clinic
featur
outcom
differ
significantli
patient
without
viral
infect
albeit
urt
symptom
frequent
posit
case
alreadi
describ
studi
picornavirus
metapneumoviru
coronavirus
common
identifi
ed
consist
recent
studi
note
rtpcr
assay
use
studi
discrimin
rhinovirus
enterovirus
howev
base
previou
investig
surmis
rhinovirus
repres
larg
major
case
strategi
also
offer
advantag
screen
newli
identifi
ed
strain
rhinoviru
c
new
respiratori
enterovirus
rtpcr
assay
alreadi
shown
abil
improv
diagnost
yield
differ
crp
elev
copd
exacerb
associ
viral
infect
system
infl
ammat
biomark
address
studi
thu
test
perform
crp
pct
indic
aecopd
pctbase
guidelin
may
lead
decreas
use
antibiot
practic
pct
valu
predefi
ned
limit
mani
clinician
consid
virus
bacteria
caus
aecopd
result
show
correl
either
crp
pct
valu
sputum
cultur
result
virolog
screen
neither
biomark
could
effi
cientli
discrimin
two
type
infect
possibl
lack
power
might
explain
result
studi
properli
power
detect
differ
pct
preclud
conclus
hypothes
howev
season
pattern
rsv
epidem
vari
substanti
everi
year
might
explain
discrep
inde
sever
studi
even
switzerland
report
biennial
activ
rsv
could
underestim
preval
copd
popul
studi
compar
studi
high
rate
viru
detect
urt
aecopd
also
support
idea
antibiot
may
overprescrib
patient
distinguish
pure
viral
infect
mix
bacteri
infect
major
import
present
studi
offer
advantag
extens
molecular
viral
screen
welldefi
ned
clinic
entiti
aecopd
known
associ
bacteri
viral
infect
biolog
marker
long
day
aecopd
believ
report
rate
viral
infect
reliabl
final
lack
relat
studi
recoveri
time
detect
virus
also
could
explain
fact
patient
mainli
refer
physician
diffi
cult
determin
precis
exact
start
exacerb
threshold
referr
differ
physician
refl
ect
diffi
culti
encount
reallif
manag
patient
copd
preval
virus
detect
nasopharyng
swab
rtpcr
high
aecopd
low
clinic
recoveri
suggest
aecopd
frequent
trigger
viral
infect
initi
urt
studi
current
biolog
marker
crp
pct
could
discrimin
viral
nonvir
aecopd
rapid
virolog
diagnost
procedur
therefor
highli
need
accur
confi
rm
viral
etiolog
presenc
copd
exacerb
subsequ
appli
appropri
treatment
strategi
level
group
furthermor
fact
onethird
patient
includ
alreadi
antibiot
admiss
may
contribut
low
pct
valu
result
refl
ect
howev
real
life
clinic
practic
thu
limit
predict
valu
pct
hospit
admiss
studi
limit
quit
possibl
studi
underestim
rate
bacteri
infect
coinfect
much
sputum
sampl
bacteri
analysi
avail
case
patient
alreadi
receiv
antibiot
convers
bacteri
assay
semiquantit
perform
bacteri
detect
followup
bacteri
colon
common
patient
copd
possibl
identifi
cation
bacteria
aecopd
necessarili
impli
etiolog
role
fi
nding
may
affect
valu
biomark
clinic
outcom
addit
patient
recruit
onset
aecopd
may
pass
peak
viral
load
could
underestim
real
preval
virusrel
aecopd
howev
given
high
sensit
rtpcr
fact
viral
nucleic
acid
detect
urt
possibl
